Shedding light
on blood flow
Shedding light
on blood flow
Shedding light
on blood flow
We develop a microfluidic-based platform to advance hematological diagnostics, assist therapy decision-making and improve patient safety.
Our technology enables a high-throughput, AI-powered assessment of the morphology and functionality of blood on a cellular level.
CES 2023 in Las Vegas
93rd Annual Meeting of The Society of Rheology
Beyond Science…
Meeting of the European Red Cell Society
Cross-talk between red blood cells and plasma of COVID-19 patients
Technology
Technology
Over 25 trillion red blood cells travel through our bodies every minute. Their shape is a highly sensitive parameter for both intrinsic cell properties and external influences. Erysense utilizes red blood cell shape features as a biomarker.
Advantages
Small sample volume
Erysense requires only one drop of blood, avoiding the need of specialized personnel for sampling and minimizing patient blood loss.
Analysis on a single-cell level
The shape of red blood cells is highly influenced by the intrinsic cell properties and external conditions. Erysense enables the examination of such effects on the morphology of individual cells at high-throughput.
Versatility
Erysense enables advanced hematological diagnosis, individualized therapy, and in-vitro drug testing.
Advantages
Small sample volume
Erysense requires only one drop of blood, avoiding the need of specialized personnel for sampling and minimizing patient blood loss.
Analysis on a single-cell level
The shape of red blood cells is highly influenced by the intrinsic cell properties and external conditions. Erysense enables the examination of such effects on the morphology of individual cells at high-throughput.
Versatility
Erysense enables advanced hematological diagnosis, individualized therapy, and in-vitro drug testing.
Applications
Blood quality assessment for transfusion medicine
Advanced hematological diagnostics
research
In-vitro testing for drug development
Biomedical technologies, e.g., cell-based drug delivery
Blood quality
assessment for
transfusion
medicine
hematological
diagnostics
Blood and cell
research
testing for drug
development
technologies, e.g.,
cell-based
drug delivery
Meet our team
Our interdisciplinary team combines scientific excellence in red blood cell research with expertise in microfluidics, cell biology, microscopy, and AI.
This diversified background motivates us to unify our strengths for a mutual goal: setting new standards in hematology with our Erysense Technology.
Advisory Board
Dr. Martin Gitzinger
Dr. Martin Gitzinger
Before that he was and continues to be a business lawyer for nearly 30 years with a wide experience in intellectual property law.
As a student, he worked on an rule based expert system on the UN Sales Law and earned his doctorate in computational logics and linguistics.
Dr. Gitzinger was one of the first shareholders of Pyrum Innovations AG, a green technology start up that recycles tires through a pyrolysis process in oil, gas and carbon black. He played an instrumental role in initiating the investors process and building a corporate culture. Pyrum was going public in 2021.
Today, he leads the development of corporate compliance and certification at Cysmic.The Erysense platform simulates microvascular blood flow in microchannels with a diameter 10X smaller than a human hair. Using an automated AI-based cell shape evaluation, Erysense constitutes a fast and robust point-of-care system for patient-centered assessment of blood functionality.
Dr. Martin Gitzinger
Dr. Martin Gitzinger
Before that he was and continues to be a business lawyer for nearly 30 years with a wide experience in intellectual property law.
As a student, he worked on an rule based expert system on the UN Sales Law and earned his doctorate in computational logics and linguistics.
Dr. Gitzinger was one of the first shareholders of Pyrum Innovations AG, a green technology start up that recycles tires through a pyrolysis process in oil, gas and carbon black. He played an instrumental role in initiating the investors process and building a corporate culture. Pyrum was going public in 2021.
Today, he leads the development of corporate compliance and certification at Cysmic.The Erysense platform simulates microvascular blood flow in microchannels with a diameter 10X smaller than a human hair. Using an automated AI-based cell shape evaluation, Erysense constitutes a fast and robust point-of-care system for patient-centered assessment of blood functionality.
Patrick Klein
Contact
info(at)cysmic.de
Starterzentrum A1 2
66123 Saarbrücken